RAMSAY HEALTH CARE LIMITED (RHC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RHC - RAMSAY HEALTH CARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 7.2
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Founded in Sydney in 1964, Ramsay Health Care is the largest provider of private healthcare in Australia, with operations in the UK, France, Indonesia and Malaysia. The company specialises in surgery, rehabilitation and psychiatric care. It was first listed in 1997.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$52.00

12 Apr
2024

-0.150

OPEN

$51.80

-0.29%

HIGH

$52.14

255,443

LOW

$51.62

TARGET
$58.602 12.7% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
RHC: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 131.4 xxx
DPS (cps) xxx N/A 76.4 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 39.5 xxx
Dividend Yield xxx N/A 1.5% xxx
Div Pay Ratio(%) xxx N/A 58.1% xxx

Dividend yield today if purchased 3 years ago: 1.11%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.44

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 11/03 - ex-div 40c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx125.1
DPS All xxxxxxxxxxxxxxx75.0
Sales/Revenue xxxxxxxxxxxxxxx14,977.1 M
Book Value Per Share xxxxxxxxxxxxxxx1,710.2
Net Operating Cash Flow xxxxxxxxxxxxxxx1,299.5 M
Net Profit Margin xxxxxxxxxxxxxxx1.86 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx6.99 %
Return on Invested Capital xxxxxxxxxxxxxxx1.87 %
Return on Assets xxxxxxxxxxxxxxx1.37 %
Return on Equity xxxxxxxxxxxxxxx6.88 %
Return on Total Capital xxxxxxxxxxxxxxx4.14 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx359.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx487 M
Long Term Debt xxxxxxxxxxxxxxx11,400 M
Total Debt xxxxxxxxxxxxxxx11,886 M
Goodwill - Gross xxxxxxxxxxxxxxx5,756 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx656 M
Price To Book Value xxxxxxxxxxxxxxx3.29

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx720.9 M
Capex % of Sales xxxxxxxxxxxxxxx4.81 %
Cost of Goods Sold xxxxxxxxxxxxxxx13,705 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx611 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx147 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

01/03/2024

1

Add

$60.76

16.85%

Ramsay Health Care's 1H results beat Morgans expectations and FY24 guidance was maintained. Management noted the margin recovery continues to be "slowed" by ongoing cost pressures and an increase in digital and data opex.

The broker highlights earnings in the UK and domestically improved, but were offset by ongoing inflationary pressures in the EU. Revenue increased in Australia, the UK and the EU by 6%, 29% and 17%, respectively.

Management noted the Elysium business continues to improve.

The target rises by $1.00 to $60.76 and the Add rating is maintained.

FORECAST
Morgans forecasts a full year FY24 dividend of 80.00 cents and EPS of 133.00 cents.
Morgans forecasts a full year FY25 dividend of 114.00 cents and EPS of 189.60 cents.

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

RHC STOCK CHART